ANI Pharmaceuticals (NASDAQ:ANIP) Shares Down 6.3% – Here’s What Happened

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)’s stock price was down 6.3% during trading on Friday . The stock traded as low as $76.46 and last traded at $75.9710. Approximately 184,812 shares changed hands during trading, a decline of 50% from the average daily volume of 370,780 shares. The stock had previously closed at $81.04.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of ANI Pharmaceuticals in a report on Monday, December 29th. Guggenheim raised their price target on ANI Pharmaceuticals from $114.00 to $115.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Zacks Research lowered shares of ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, January 6th. HC Wainwright increased their price objective on shares of ANI Pharmaceuticals from $93.00 to $121.00 and gave the company a “buy” rating in a research note on Wednesday, September 17th. Finally, JPMorgan Chase & Co. raised their target price on shares of ANI Pharmaceuticals from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, September 24th. Six research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $102.14.

ANI Pharmaceuticals Stock Down 5.9%

The stock has a market cap of $1.71 billion, a price-to-earnings ratio of 46.80 and a beta of 0.51. The company has a current ratio of 2.58, a quick ratio of 2.04 and a debt-to-equity ratio of 1.20. The firm’s 50 day moving average is $82.81 and its two-hundred day moving average is $83.17.

ANI Pharmaceuticals (NASDAQ:ANIP) last issued its quarterly earnings results on Friday, November 7th. The specialty pharmaceutical company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.74 by $0.30. The business had revenue of $227.81 million during the quarter, compared to the consensus estimate of $211.92 million. ANI Pharmaceuticals had a net margin of 4.91% and a return on equity of 26.73%. The company’s quarterly revenue was up 53.6% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.34 earnings per share. ANI Pharmaceuticals has set its FY 2025 guidance at 7.370-7.640 EPS. On average, sell-side analysts predict that ANI Pharmaceuticals, Inc. will post 3.86 EPS for the current year.

Insider Transactions at ANI Pharmaceuticals

In other news, SVP Chad Gassert sold 14,642 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, November 12th. The stock was sold at an average price of $89.07, for a total value of $1,304,162.94. Following the completion of the sale, the senior vice president owned 158,584 shares of the company’s stock, valued at $14,125,076.88. The trade was a 8.45% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Patrick D. Walsh sold 8,643 shares of the company’s stock in a transaction on Thursday, November 13th. The shares were sold at an average price of $86.88, for a total value of $750,903.84. Following the completion of the transaction, the director owned 61,405 shares of the company’s stock, valued at $5,334,866.40. The trade was a 12.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 28,001 shares of company stock worth $2,446,934 in the last three months. 11.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Assenagon Asset Management S.A. increased its position in ANI Pharmaceuticals by 259.4% during the third quarter. Assenagon Asset Management S.A. now owns 46,328 shares of the specialty pharmaceutical company’s stock worth $4,244,000 after purchasing an additional 33,438 shares during the last quarter. Intech Investment Management LLC grew its stake in shares of ANI Pharmaceuticals by 134.7% during the 2nd quarter. Intech Investment Management LLC now owns 26,917 shares of the specialty pharmaceutical company’s stock valued at $1,756,000 after buying an additional 15,447 shares during the period. Squarepoint Ops LLC acquired a new stake in shares of ANI Pharmaceuticals during the 2nd quarter worth $2,137,000. Envestnet Asset Management Inc. increased its holdings in shares of ANI Pharmaceuticals by 59.9% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,326 shares of the specialty pharmaceutical company’s stock worth $674,000 after buying an additional 3,869 shares during the last quarter. Finally, Exchange Traded Concepts LLC purchased a new position in shares of ANI Pharmaceuticals in the 3rd quarter worth $775,000. Institutional investors and hedge funds own 76.05% of the company’s stock.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.